Publicaciones en colaboración con investigadores/as de University of Alabama at Birmingham (17)

2021

  1. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

    Journal of the American College of Cardiology, Vol. 78, Núm. 5, pp. 421-433

2020

  1. Endoscopic ultrasound as a diagnostic and predictive tool in idiopathic acute pancreatitis

    Annals of Gastroenterology, Vol. 33, Núm. 3, pp. 305-312

2019

  1. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

  2. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 12, pp. 899-911

2018

  1. Alirocumab and cardiovascular outcomes after acute coronary syndrome

    New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107

  2. Evaluation and management of acute pancreatitis in Spain

    Gastroenterologia y Hepatologia

  3. Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations

    PLoS ONE, Vol. 13, Núm. 1

2016

  1. Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 1, pp. 242-252

2015

  1. Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus

    Clinical Immunology, Vol. 161, Núm. 2, pp. 157-162

2013

  1. Increased CD38 expression in T cells and circulating anti-CD38 IgG autoantibodies differentially correlate with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients

    Cytokine, Vol. 62, Núm. 2, pp. 232-243

  2. Preferential Binding to Elk-1 by SLE-Associated IL10 Risk Allele Upregulates IL10 Expression

    PLoS Genetics, Vol. 9, Núm. 10

  3. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

    New England Journal of Medicine, Vol. 369, Núm. 14, pp. 1317-1326

2012

  1. Altered AKT1 and MAPK1 gene expression on peripheral blood mononuclear cells and correlation with T-helper-transcription factors in Systemic Lupus Erythematosus patients

    Mediators of Inflammation, Vol. 2012

  2. Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus

    Annals of the Rheumatic Diseases, Vol. 71, Núm. 5, pp. 694-699

2011

  1. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort

    Genes and Immunity, Vol. 12, Núm. 4, pp. 270-279

  2. The functional polymorphism 844 A>G in Fc αRI (CD89) does not contribute to systemic sclerosis or rheumatoid arthritis susceptibility

    Journal of Rheumatology, Vol. 38, Núm. 3, pp. 446-449

2009

  1. Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans

    Journal of Clinical Investigation, Vol. 119, Núm. 4, pp. 911-923